exRNAdisease

Entry Detail

---



General Information

Database ID: exR0275624 RNA Name: hsa-miR-449a RNA Type: miRNA Chromosome: chr5 Starnd: - Coordinate: Start Site(bp): 55170586 End Site(bp): 55170607 External Links: hsa-miR-449a

Disease Information

Disease Name: Advanced Adenoma Disease Category: Cancers MeSH ID: D000236 Type: Neoplasms/Neoplasms, Glandular and Epithelial Alias: Adenoma//Adenomas//Adenoma, Follicular//Adenomas, Follicular//Follicular Adenoma//Follicular Adenomas//Adenoma, Trabecular//Adenomas, Trabecular//Trabecular Adenoma//Trabecular Adenomas//Adenoma, Monomorphic//Adenomas, Monomorphic//Monomorphic Adenoma//Monomorphic Adenomas//Adenoma, Papillary//Adenomas, Papillary//Papillary Adenoma//Papillary Adenomas//Adenoma, Basal Cell//Adenomas, Basal Cell//Basal Cell Adenoma//Basal Cell Adenomas//Adenoma, Microcystic//Adenomas, Microcystic//Microcystic Adenoma//Microcystic Adenomas

Expression Detail

GEO ID: GSE25609 Description: Plasma microRNA profiling by microarray elucidates several candidate biomarkers for colorectal cancer screening Experimental Design: Cancer vs Control Case Disease Type: Advanced Adenoma Case Disease SubType: NA Case Sample: Advanced Adenoma Post surgery Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AKAP13 chr15 85380571 85749358 + UBXN2B chr8 58411359 58451501 + ACSL1 chr4 184755595 184826818 - CALM3 chr19 46601074 46610782 + SUPT6H chr17 28662198 28702679 + STK38L chr12 27243968 27325959 + NPTX1 chr17 80466834 80477843 - PPARD chr6 35342558 35428191 + MID1 chrX 10445310 10833654 - PER2 chr2 238244044 238290102 - C2CD5 chr12 22448583 22544546 - GNA12 chr7 2728105 2844308 - DEDD2 chr19 42198598 42220140 - PHF19 chr9 120855651 120894896 - CCDC86 chr11 60842113 60851081 + PRR12 chr19 49591182 49626439 + ATXN2L chr16 28823035 28837237 + MLLT1 chr19 6210381 6279975 - ANGEL1 chr14 76786168 76826246 - CD151 chr11 832887 839831 + NTN4 chr12 95657807 95791152 - DLL1 chr6 170282206 170306565 - ZNF512B chr20 63956704 63969930 - NCOA1 chr2 24491914 24770702 + ZNF623 chr8 143636013 143656418 + HOXB8 chr17 48611377 48615292 - JPH1 chr8 74234700 74321540 - CRTC3 chr15 90529923 90645345 + TMEM109 chr11 60914158 60923443 + ZDHHC17 chr12 76763588 76853696 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001723 chr7 91924202 91948826 + hsa_circ_0001495 chr5 68470703 68471364 + hsa_circ_0000943 chr19 47421744 47440665 + hsa_circ_0000038 chr1 28800065 28802803 + hsa_circ_0001865 chr9 86292641 86293514 - hsa_circ_0001146 chr20 34241449 34246936 - hsa_circ_0001164 chr20 45891031 45923523 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC018521.1 chr17 47945424 47981736 + AC116913.1 chr15 66488658 66492109 - HCG18 chr6 30286690 30327382 - KCNQ1OT1 chr11 2608328 2699994 - LINC00665 chr19 36313067 36331770 - NEAT1 chr11 65422774 65445540 + SNHG7 chr9 136721366 136728184 - TERC chr3 169764520 169765060 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE25609 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 826 Sample treatment protocol: Briefly, samples were centrifuged at 1,600×g for 10 min at 4 ºC to spin down blood cells, and plasma was transferred into new tubes, followed by further centrifugation at 16,000×g for 10 minutes at 4ºC to completely remove cellular components. RNA Extract protocol: NA RNA library preparation protocol: Biotinylated cDNA were prepared with the Illumina® TotalPrep™ RNA Amplification Kit (Ambion).

Reference

PMID: 23267864 Title: Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study Author: Gir¨¢ldez MD, Lozano JJ, Ram¨ªrez G, Hijona E, Bujanda L, Castells A, Gironella M Journal: Clin Gastroenterol Hepatol. 2013 Jun;11(6):681-8.e3. Description: We investigated whether plasma levels of miRNA can differentiate patients with CRC from healthy individuals. We also investigated whether plasma samples from patients with premalignant neoplastic lesions, such as advanced adenomas (AAs), also had a different expression pattern of miRNAs.